Urogen Pharma Ltd UGN-102 and Non-Muscle Invasive Bladder Cancers Briefing Transcript
Good morning, and welcome to the UroGen Pharma KOL webinar. (Operator Instructions) A question-and-answer session will follow the formal presentations. (Operator Instructions) As a reminder, this call is being recorded and a replay will be made available on the UroGen website following the conclusion of the event.
I'd now like to turn the call over to Vincent Perrone, Senior Director of Investor Relations. Please go ahead, Vincent.
Good morning, everyone. As Tara mentioned, my name is Vincent Perrone, Head of Investor Relations for UroGen Pharma. I'd like to welcome you to UroGen's key opinion leader webinar for investors and analysts. The topic for today's webinar will cover the unmet need and treatment landscape for non-muscle invasive bladder cancers, or NMIBC, with a focus on low-grade, intermediate-risk NMIBC.
Next slide. Before we begin, let me remind you that during today's call, the company will be making forward-looking statements concerning future events,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
